Post by Amylyx Pharmaceuticals

Among the roughly two million people in the U.S. who have had a Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy in the past decade, an estimated 160,000 are living with post-bariatric hypoglycemia (PBH), which is a rare, chronic condition with no FDA-approved treatments. PBH is characterized by hyperinsulinemic hypoglycemia, which can cause debilitating symptoms as the body responds to rapid changes in blood glucose levels. Learn more about PBH on our website at https://bit.ly/4t6RTSV